JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Productos de "JAK"
Ordenar por
AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Fórmula:C29H28F3N5O2Pureza:98%Forma y color:SolidPeso molecular:535.56Ruxolitinib
CAS:Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.Fórmula:C17H18N6Pureza:100% - 99.99%Forma y color:SolidPeso molecular:306.36Ref: TM-T1829
5mg58,00€10mg74,00€25mg92,00€50mg116,00€100mg155,00€200mg245,00€500mg414,00€1mL*10mM (DMSO)65,00€SHR0302
CAS:SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,Fórmula:C18H22N8O2SPureza:99.11%Forma y color:SolidPeso molecular:414.48Ref: TM-T9195
1mg160,00€5mg393,00€10mg620,00€25mg1.035,00€50mg1.483,00€100mg1.882,00€1mL*10mM (DMSO)455,00€lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Fórmula:C16H25N5OSForma y color:SolidPeso molecular:335.468JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Fórmula:C23H22FN5O4SPureza:99.57%Forma y color:SolidPeso molecular:483.52Tofacitinib
CAS:Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.Fórmula:C16H20N6OPureza:100% - 99.71%Forma y color:SolidPeso molecular:312.37JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67AZD-1480
CAS:AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.Fórmula:C14H14ClFN8Pureza:97.5% - 98.55%Forma y color:SolidPeso molecular:348.77TG101209
CAS:TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.Fórmula:C26H35N7O2SPureza:100% - 99.36%Forma y color:SolidPeso molecular:509.67JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nMFórmula:C20H21F2N7OPureza:98%Forma y color:SolidPeso molecular:413.42JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Fórmula:C31H31F3N8O4Forma y color:SolidPeso molecular:639.64Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Fórmula:C27H36N6O3SPureza:98.23% - 99.96%Forma y color:SolidPeso molecular:524.68Ref: TM-T1995
1g625,00€5mg49,00€10mg69,00€50mg113,00€100mg134,00€200mg216,00€500mg472,00€1mL*10mM (DMSO)57,00€Pyridone 6
CAS:Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Fórmula:C18H16FN3OPureza:97.10% - 98.74%Forma y color:SolidPeso molecular:309.34Ref: TM-T3080
1mg82,00€2mg106,00€5mg162,00€10mg221,00€25mg449,00€50mg658,00€100mg939,00€500mg1.882,00€1mL*10mM (DMSO)177,00€Baricitinib
CAS:Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Fórmula:C16H17N7O2SPureza:100% - 99.79%Forma y color:SolidPeso molecular:371.42Ref: TM-T2485
5mg50,00€10mg73,00€25mg90,00€50mg115,00€100mg144,00€200mg188,00€500mg311,00€1mL*10mM (DMSO)69,00€JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Fórmula:C26H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:521.59Filgotinib
CAS:Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Forma y color:SolidPeso molecular:425.5JAK2 Inhibitor V
CAS:JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.Fórmula:C23H24N2OPureza:96.69% - 99.15%Forma y color:SolidPeso molecular:344.45Ref: TM-T3042
2mg39,00€5mg57,00€10mg85,00€25mg157,00€50mg274,00€100mg505,00€500mg1.121,00€1mL*10mM (DMSO)63,00€DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstratingFórmula:C36H40Cl2N2O10PtPureza:98%Forma y color:SolidPeso molecular:926.7AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H14FN5OForma y color:SolidPeso molecular:323.32TCS 21311
CAS:TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Fórmula:C27H25F3N4O4Pureza:≥98%Forma y color:SolidPeso molecular:526.51Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Fórmula:C17H18N6Pureza:99.37% - 99.79%Forma y color:SolidPeso molecular:306.36JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.Fórmula:C20H24N6O2SPureza:98%Forma y color:SolidPeso molecular:412.514-(3'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE, HCL
CAS:Fórmula:C16H16ClN3O3Pureza:97.0%Peso molecular:333.7695AG490
CAS:AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Forma y color:Yellow SolidPeso molecular:294.3BD750
CAS:BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM inFórmula:C14H13N3OSPureza:99.02%Forma y color:SolidPeso molecular:271.34WHI-P180 Hydrochloride
CAS:Fórmula:C16H15N3O3·HClPureza:>97.0%(T)(HPLC)Forma y color:White to Light gray to Light yellow powder to crystalPeso molecular:333.77Fedratinib hydrochloride hydrate
CAS:Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.46%Forma y color:SolidPeso molecular:615.61JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Fórmula:C18H20N4O3Pureza:98.04% - 98.19%Forma y color:SolidPeso molecular:340.38Ref: TM-T11704
1mg133,00€2mg188,00€5mg321,00€10mg518,00€25mg1.035,00€50mg1.644,00€100mg2.680,00€200mg3.591,00€1mL*10mM (DMSO)354,00€Momelotinib Mesylate
CAS:Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Fórmula:C24H26N6O5SPureza:98%Forma y color:SolidPeso molecular:510.57Delgocitinib
CAS:Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Fórmula:C16H18N6OPureza:99.90%Forma y color:SolidPeso molecular:310.35Ref: TM-T15096
1mg169,00€5mg311,00€10mg487,00€25mg929,00€50mg1.415,00€100mg2.062,00€200mg2.775,00€1mL*10mM (DMSO)349,00€CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Fórmula:C18H18N4Forma y color:SolidPeso molecular:290.36LFM-A13
CAS:LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR,Fórmula:C11H8Br2N2O2Pureza:99.9%Forma y color:SolidPeso molecular:360JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].Fórmula:C15H17N7Pureza:98%Forma y color:SolidPeso molecular:295.34Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Fórmula:C24H25N7O2Forma y color:SolidPeso molecular:443.50Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Fórmula:C18H21F2N7OPureza:99.8%Forma y color:SolidPeso molecular:389.4Ref: TM-TQ0010
1mg35,00€5mg74,00€10mg110,00€25mg226,00€50mg411,00€100mg660,00€200mg917,00€1mL*10mM (DMSO)81,00€RO8191
CAS:RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.Fórmula:C14H5F6N5OPureza:98.85% - ≥98%Forma y color:SolidPeso molecular:373.21MM-589 TFA
CAS:MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C30H45F3N8O7Pureza:98%Forma y color:SolidPeso molecular:686.72Atractylenolide I
CAS:Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.Fórmula:C15H18O2Pureza:97.55% - 99.83%Forma y color:SolidPeso molecular:230.3AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H13ClFN5OForma y color:SolidPeso molecular:357.77WDR5-IN-6
CAS:WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6Fórmula:C13H8Cl2N2O2SPureza:99.69%Forma y color:SoildPeso molecular:327.19JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Fórmula:C17H19F2N7OSPureza:98%Forma y color:SolidPeso molecular:407.44ITK inhibitor 2
CAS:ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Fórmula:C25H33N5O2Forma y color:SolidPeso molecular:435.56JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Fórmula:C21H19N7O2S2Pureza:98%Forma y color:SolidPeso molecular:465.55G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Fórmula:C22H19F2NO3Pureza:97.30%Forma y color:SolidPeso molecular:383.39Ref: TM-T8742
1mg50,00€5mg97,00€10mg145,00€25mg259,00€50mg374,00€100mg523,00€200mg710,00€1mL*10mM (DMSO)105,00€RO495
CAS:RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFórmula:C17H14Cl2N6OPureza:97.94%Forma y color:SolidPeso molecular:389.24Ref: TM-T22416
1mg64,00€2mg87,00€5mg117,00€10mg183,00€25mg354,00€50mg520,00€100mg702,00€200mg944,00€1mL*10mM (DMSO)140,00€Protosappanin A
CAS:Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.Fórmula:C15H12O5Pureza:100% - 99.42%Forma y color:SolidPeso molecular:272.25Ref: TM-TJS1779
1mg87,00€5mg216,00€10mg354,00€25mg582,00€50mg825,00€100mg1.111,00€1mL*10mM (DMSO)197,00€Momelotinib
CAS:Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.Fórmula:C23H22N6O2Pureza:97.47% - 99.56%Forma y color:SolidPeso molecular:414.46Ref: TM-T1849
1mg38,00€2mg49,00€5mg81,00€10mg95,00€25mg166,00€50mg259,00€100mg406,00€200mg625,00€1mL*10mM (DMSO)88,00€JAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,Fórmula:C27H26N6OPureza:98%Forma y color:SolidPeso molecular:450.53JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Fórmula:C25H32N8O2Pureza:99.64%Forma y color:SolidPeso molecular:476.57GLPG0634 analog
CAS:GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.Fórmula:C23H18N6O2Pureza:100% - 99.22%Forma y color:SolidPeso molecular:410.43Ref: TM-T3076
1mg40,00€2mg52,00€5mg88,00€10mg144,00€25mg264,00€50mg465,00€100mg658,00€500mg1.378,00€1mL*10mM (DMSO)87,00€XL019
CAS:XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.Fórmula:C25H28N6O2Pureza:99.19%Forma y color:SolidPeso molecular:444.53WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Forma y color:SolidPeso molecular:356.22SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Fórmula:C15H8Cl2FN3OPureza:99.56%Forma y color:SolidPeso molecular:336.15Ref: TM-T8719
1mg46,00€5mg93,00€10mg140,00€25mg240,00€50mg363,00€100mg452,00€200mg630,00€1mL*10mM (DMSO)99,00€SAR-20347
CAS:SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).Fórmula:C21H18ClFN4O4Pureza:99.35% - 99.77%Forma y color:SolidPeso molecular:444.84Ref: TM-T4210
1mg35,00€5mg80,00€10mg116,00€25mg227,00€50mg354,00€100mg588,00€200mg818,00€1mL*10mM (DMSO)88,00€BMS-911543
CAS:BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.Fórmula:C23H28N8OPureza:97.69% - 99.98%Forma y color:SolidPeso molecular:432.52Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Fórmula:C18H19F3N6OPureza:100% - 99.45%Forma y color:SolidPeso molecular:392.38Ref: TM-T2636
1mg38,00€2mg52,00€5mg79,00€10mg110,00€25mg217,00€50mg329,00€100mg494,00€200mg705,00€1mL*10mM (DMSO)88,00€CHZ868
CAS:CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.Fórmula:C22H19F2N5O2Pureza:99.38%Forma y color:SolidPeso molecular:423.42Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Fórmula:C20H20N4O2SForma y color:SolidPeso molecular:380.463Ilginatinib
CAS:Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H20FN7Pureza:98.40% - 99.01%Forma y color:SolidPeso molecular:389.43Ref: TM-T12266
1mg64,00€5mg138,00€10mg187,00€25mg273,00€50mg393,00€100mg562,00€200mg743,00€1mL*10mM (DMSO)133,00€JANEX-1
CAS:JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.Fórmula:C16H15N3O3Pureza:98% - 99.73%Forma y color:SolidPeso molecular:297.31Ref: TM-T2045
1mg44,00€2mg55,00€5mg92,00€10mg150,00€25mg248,00€50mg444,00€100mg652,00€500mg1.378,00€1mL*10mM (DMSO)92,00€MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C28H44N8O5Pureza:98%Forma y color:SolidPeso molecular:572.70Povorcitinib phosphate
CAS:Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.Fórmula:C23H25F5N7O5PPureza:97.71%Forma y color:SolidPeso molecular:605.45Ref: TM-T39113L
1mg65,00€2mg95,00€5mg145,00€10mg212,00€25mg359,00€50mg512,00€100mg695,00€200mg937,00€JAK-IN-33
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].Pureza:98%Forma y color:Odour SolidPeficitinib
CAS:Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Forma y color:SolidPeso molecular:326.39Ref: TM-T6933
2mg40,00€5mg66,00€10mg104,00€25mg182,00€50mg283,00€100mg439,00€200mg645,00€1mL*10mM (DMSO)73,00€FLLL32
CAS:FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Fórmula:C28H32O6Pureza:96.39% - 97.90%Forma y color:SolidPeso molecular:464.55Ref: TM-T6838
2mg46,00€5mg66,00€10mg93,00€25mg124,00€50mg197,00€100mg350,00€500mg840,00€1mL*10mM (DMSO)72,00€Cerdulatinib hydrochloride
CAS:Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.Fórmula:C20H28ClN7O3SPureza:99.23%Forma y color:SolidPeso molecular:482Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Fórmula:C20H18FN5O3Pureza:98.05%Forma y color:SolidPeso molecular:395.39JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Fórmula:C20H18FN5O3SPureza:98.88%Forma y color:SolidPeso molecular:427.45Ref: TM-T13571
1mg87,00€5mg177,00€10mg260,00€25mg429,00€50mg605,00€100mg815,00€500mg1.624,00€1mL*10mM (DMSO)188,00€Cerdulatinib
CAS:Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Forma y color:SolidPeso molecular:445.54Ref: TM-T2487
1mg44,00€2mg55,00€5mg79,00€10mg106,00€25mg185,00€50mg283,00€100mg432,00€200mg605,00€500mg938,00€1mL*10mM (DMSO)86,00€Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Forma y color:SolidPeso molecular:504.49TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFórmula:C28H32N4O3SPureza:97.38% - 99.1%Forma y color:SolidPeso molecular:504.64Brevilin A
CAS:Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Fórmula:C20H26O5Pureza:100% - 99.74%Forma y color:SolidPeso molecular:346.42Ref: TM-T4672
1mg96,00€5mg215,00€10mg369,00€25mg610,00€50mg840,00€100mg1.130,00€500mg2.308,00€1mL*10mM (DMSO)235,00€Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H21ClFN7Pureza:99.55%Forma y color:SolidPeso molecular:425.89Ref: TM-T12266L2
1mg77,00€5mg165,00€10mg240,00€25mg408,00€50mg562,00€100mg800,00€200mg1.074,00€1mL*10mM (DMSO)177,00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Fórmula:C16H13Cl2N3O2Pureza:98.77%Forma y color:SolidPeso molecular:350.2JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Fórmula:C27H32ClFN6OForma y color:SolidPeso molecular:511.03JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFórmula:C19H18N4O3Pureza:97.46% - 99.94%Forma y color:SolidPeso molecular:350.37Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Fórmula:C19H19F2N7O3Forma y color:SolidPeso molecular:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Fórmula:C28H38N6O5SPureza:98%Forma y color:SolidPeso molecular:570.7Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Fórmula:C25H26F2N6O2Pureza:98.71%Forma y color:SoildPeso molecular:480.51Ref: TM-T67907
1mg96,00€2mg139,00€5mg227,00€10mg354,00€25mg653,00€50mg938,00€100mg1.454,00€500mg2.822,00€JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Fórmula:C14H10ClN3OS2Pureza:99.38%Forma y color:SolidPeso molecular:335.83JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFórmula:C22H17FN6O2SPureza:98%Forma y color:SolidPeso molecular:448.47Brepocitinib P-Tosylate
CAS:Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Forma y color:SolidPeso molecular:561.6Dual Cathepsin L/JAK-IN-1
CAS:DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Fórmula:C19H18ClN5Forma y color:SolidPeso molecular:351.833Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Fórmula:C12H12N4O5Forma y color:SolidPeso molecular:292.25AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Forma y color:SolidPeso molecular:381.43Ref: TM-T3068
1mg47,00€2mg60,00€5mg95,00€10mg170,00€25mg299,00€50mg499,00€100mg723,00€1mL*10mM (DMSO)97,00€Pacritinib
CAS:Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Forma y color:SolidPeso molecular:472.58Upadacitinib
CAS:Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.Fórmula:C17H19F3N6OPureza:98.96% - 99.93%Forma y color:SolidPeso molecular:380.37Ref: TM-T7503
1mg47,00€2mg62,00€5mg89,00€10mg130,00€25mg220,00€50mg306,00€100mg434,00€200mg662,00€500mg1.169,00€1mL*10mM (DMSO)48,00€Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Forma y color:SolidPeso molecular:469.94Ref: TM-T2638
5mg51,00€10mg88,00€25mg160,00€50mg296,00€100mg469,00€500mg1.035,00€1mL*10mM (DMSO)57,00€JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Fórmula:C26H33N7OPureza:98.71%Forma y color:SolidPeso molecular:459.59Ref: TM-T35900
1mg145,00€5mg354,00€10mg630,00€25mg1.301,00€50mg1.738,00€100mg2.357,00€1mL*10mM (DMSO)358,00€AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Fórmula:C20H28FN7Pureza:98%Forma y color:SolidPeso molecular:385.48JAK-IN-28
CAS:JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Fórmula:C20H18ClN7OPureza:98%Forma y color:SolidPeso molecular:407.86JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38Tyrphostin AG 490
CAS:Fórmula:C17H14N2O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:294.31DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Fórmula:C26H35N7O5Forma y color:SolidPeso molecular:525.6Pumecitinib
CAS:Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Fórmula:C17H20N8O2SPureza:99.89%Forma y color:SoildPeso molecular:400.46RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Fórmula:C29H35N7O4Pureza:97.29% - 99.91%Forma y color:SolidPeso molecular:545.63Fosifidancitinib
CAS:Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.Fórmula:C21H21FN5O7PPureza:99.55%Forma y color:SolidPeso molecular:505.39Ref: TM-T38624
1mg87,00€2mg124,00€5mg187,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.159,00€STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFórmula:C18H24Cl2N2O6PtPureza:98%Forma y color:SolidPeso molecular:630.38
